• Login
    View Item 
    •   Home
    • The Christie Research Publications Repository
    • All Christie Publications
    • View Item
    •   Home
    • The Christie Research Publications Repository
    • All Christie Publications
    • View Item
    JavaScript is disabled for your browser. Some features of this site may not work without it.

    Browse

    All of ChristieCommunitiesTitleAuthorsIssue DateSubmit DateSubjectsThis CollectionTitleAuthorsIssue DateSubmit DateSubjectsProfilesView

    My Account

    LoginRegister

    Local Links

    The Christie WebsiteChristie Library and Knowledge Service

    Statistics

    Display statistics

    Stage- and CA125-related survival in patients with epithelial ovarian cancer treated at a cancer center.

    • CSV
    • RefMan
    • EndNote
    • BibTex
    • RefWorks
    Authors
    Board, Ruth E
    Bruijns, C T P H
    Pronk, A E
    Ryder, W David J
    Wilkinson, Peter M
    Welch, Richard
    Shanks, Jonathan H
    Connolly, G
    Slade, Richard J
    Reynolds, K
    Kitchener, Henry C
    Jayson, Gordon C
    Show allShow less
    Affiliation
    Cancer Research UK Department of Medical Oncology, Christie Hospital, Manchester, United Kingdom. ruth.board@christie-tr.nwest.nhs.uk
    Issue Date
    2006
    
    Metadata
    Show full item record
    Abstract
    Current accepted prognostic indicators in ovarian cancer include performance status, surgical (FIGO) staging, and residual disease after operation. Here we present data from a prospective analysis of patients with ovarian cancer treated at the Christie Hospital. We confirm the independent prognostic effects of FIGO staging, performance status, and residual disease in our group of patients and furthermore show that CA125 levels at presentation to the oncology service are of independent prognostic significance (P= 0.02). We present survival data and show that the 3-year, cancer-specific survival for stage I disease is 90%. We postulate that this good survival may in part be due to the use of computed tomography scanning at presentation to allow accurate staging. Further clinical trials are needed to test whether combinations of surgical, histologic, biochemical, and radiologic parameters can be used to identify a population with such a good prognosis that adjuvant therapy is not required.
    Citation
    Stage- and CA125-related survival in patients with epithelial ovarian cancer treated at a cancer center., 16 Suppl 1:18-24 Int. J. Gynecol. Cancer
    Journal
    International Journal of Gynecological Cancer
    URI
    http://hdl.handle.net/10541/72837
    DOI
    10.1111/j.1525-1438.2006.00308.x
    PubMed ID
    16515562
    Type
    Article
    Language
    en
    ISSN
    1048-891X
    ae974a485f413a2113503eed53cd6c53
    10.1111/j.1525-1438.2006.00308.x
    Scopus Count
    Collections
    All Christie Publications
    All Paterson Institute for Cancer Research

    entitlement

    Related articles

    • Combined score of pretreatment platelet count and CA125 level (PLT-CA125) stratified prognosis in patients with FIGO stage IV epithelial ovarian cancer.
    • Authors: Chen JP, Huang QD, Wan T, Tu H, Gu HF, Cao JY, Liu JH
    • Issue date: 2019 Jul 31
    • Perioperative changes in serum CA125 levels: a prognostic factor for disease-specific survival in patients with ovarian cancer.
    • Authors: Zwakman N, van de Laar R, Van Gorp T, Zusterzeel PL, Snijders MP, Ferreira I, Massuger LF, Kruitwagen RF
    • Issue date: 2017 Jan
    • Significance of serum CA125 and TPS antigen levels for determination of overall survival after three chemotherapy courses in ovarian cancer patients during long-term follow-up.
    • Authors: van Dalen A, Favier J, Hallensleben E, Burges A, Stieber P, de Bruijn HW, Fink D, Ferrero A, McGing P, Harlozinska A, Kainz Ch, Markowska J, Molina R, Sturgeon C, Bowman A, Einarsson R, Goike H
    • Issue date: 2009
    • High levels of pretreatment CA125 are associated to improved survival in high grade serous ovarian carcinoma.
    • Authors: Morales-Vásquez F, Pedernera E, Reynaga-Obregón J, López-Basave HN, Gómora MJ, Carlón E, Cárdenas S, Silva-Ayala R, Almaraz M, Méndez C
    • Issue date: 2016 Jul 7
    • Preoperative CA 125: an independent prognostic factor in patients with stage I epithelial ovarian cancer.
    • Authors: Nagele F, Petru E, Medl M, Kainz C, Graf AH, Sevelda P
    • Issue date: 1995 Aug

    Related items

    Showing items related by title, author, creator and subject.

    • Thumbnail

      Treatment for non small cell lung cancer, small cell lung cancer and pleural mesothelioma within the EORTC Lung Cancer Group: past, present and future.

      O'Brien, M; van Meerbeeck, J; Surmont, V; Faivre-Finn, Corinne (2012)
    • Thumbnail

      Ovarian cancer among 8,005 women from a breast cancer family history clinic: no increased risk of invasive ovarian cancer in families testing negative for BRCA1 and BRCA2.

      Ingham, S; Warwick, J; Buchan, I; Sahin, S; O'Hara, Catherine; Moran, Anthony; Howell, Anthony; Evans, D; Centre for Health Informatics, Institute of Population Health, The University of Manchester, Manchester, UK. (2013-06)
      Mutations in BRCA1/2 genes confer ovarian, alongside breast, cancer risk. We examined the risk of developing ovarian cancer in BRCA1/2-positive families and if this risk is extended to BRCA negative families.
    • Thumbnail

      AZD8186 study 1: phase I study to assess the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD) and preliminary anti-tumour activity of AZD8186 in patients with advanced castration-resistant prostate cancer (CRPC), squamous non-small cell lung cancer, triple negative breast cancer and with PTEN-deficient/mutated or PIK3CB mutated/amplified malignancies, as monotherapy and in combination with vistusertib (AZD2014) or abiraterone acetate.

      Lillian, S; De Bono, J; Higano, C; Shapiro, G; Brugger, W; Mitchell, P; Colebrook, S; Klinowska, T; Barry, S; Dean, Emma J; et al. (2016-12)
    DSpace software (copyright © 2002 - 2025)  DuraSpace
    Quick Guide | Contact Us
    Open Repository is a service operated by 
    Atmire NV
     

    Export search results

    The export option will allow you to export the current search results of the entered query to a file. Different formats are available for download. To export the items, click on the button corresponding with the preferred download format.

    By default, clicking on the export buttons will result in a download of the allowed maximum amount of items.

    To select a subset of the search results, click "Selective Export" button and make a selection of the items you want to export. The amount of items that can be exported at once is similarly restricted as the full export.

    After making a selection, click one of the export format buttons. The amount of items that will be exported is indicated in the bubble next to export format.